...

Why Kenya Relies on Indian Generic Medicine Imports (2026)

When a Kenyan patient obtains antiretrovirals for HIV, metformin for diabetes, or artemether lumefantrine for malaria, whether from a county hospital or a private chemist, there is a high likelihood that the medicine was manufactured in India or made in Kenya from ingredients sourced from India.

This is the reality for Indian generic medicines in Kenya, and it informs most discussions on the supply, price, and quality of medicines.

The focus on Indian medicines is not without reason.

It is primarily due to high and rising demand, economic factors that favour production of large volumes of low-cost generics, and the long-standing relationship between Indian pharmaceutical companies and the scaling up of HIV treatment in Africa.

More recently, donor funding shocks and enhanced emphasis on medicine quality by the Kenyan Government, and a will by the government to improve local medicine production, are also likely to test the strength of this relationship.

The article traces the path of dependence on Indian medicines, locates the points of fragility, and explains how medicines are procured and where the relationship is headed.

It is primarily meant for the exporter reflecting on the Kenyan market, distributors doing registrations and tenders, and analysts trying to decipher the numbers.

A Large Need Kenya Cannot Yet Supply Itself

A dual disease burden driving demand

Kenya has a double burden of communicable and non-communicable diseases.

The Ministry of Health reported 1.4 million people living with HIV.[1]

It also reported that as of 2021, 96% of HIV positive Kenyans were on Antiretroviral Treatment.

HIV positivity is not the only challenge.

kenya healthcare market infographic

Statistics show that Malaria accounts for 3.5 million new cases and 10,700 deaths[2] in Kenya, annually.

Non-communicable diseases are also emerging.

In 2014, Non-Communicable Diseases accounted for 27% of total deaths in Kenya. By 2020, this proportion increased to 39%.[3]

Also, in 2020, 51% of people who died from Non-Communicable Diseases were below the age of 40 years.

Other challenges related to chronic and non-chronic diseases also persist.

Long-term treatment for such conditions leads to sustained, high demand for the same medicines.

Kenya has the 7th highest HIV burden in the world,[4] and Malaria affected 11.7% of the population in 2022.

A domestic industry that meets only part of the need

There is a significant demand that local supply can’t meet.

Local producers make about 30% of what is demanded in Kenya.[5]

About 20-30% of the drug supply will be met locally by 2026.[6]

a domestic industry that meets only part of the need

Around 220 drugs out of the 1012 on the Kenya Essential Medicines List are made locally.

Even with a host of challenges, Kenya remains the largest pharmaceutical producer in East Africa.

There are over 37 licensed manufacturers. The continent exports over $15 billion worth of pharmaceutical products.

There is a severe dependency on imports, as Africa imports more than 95%[7] of its demand for Active Pharmaceutical Ingredients (APIs).

Where there is local supply, it is often lower-capacity production.

Countries in East Africa rely on Kenya for drug supply.

Tanzania takes 21% of pharmaceutical products exported by Kenya, and Uganda takes 20% of Kenya’s exports.

The primary means to close that gap for buyers are finished formulations or APIs and a Kenya sourcing guide.

Why India Fills the Gap

Kenya can trade with almost any nation, but it imports mostly from India.

Between January and March 2026, India accounted for 37- 45 per cent of the value of Kenya’s pharmaceutical imports.

Here are four reasons for this, and they all build on each other.

why india fills the gap

Cost and scale: Indian generics are cheap and plentiful – exactly what the budget-constrained system needs. An export-promotion study of Kenya’s pharmaceutical market reported that low per capita income gives an edge to low-priced products.

Similar trends can be seen in Kenya’s annual procurement data: in the 2017/18 fiscal year, Kenya spent 23% less per ton of medicines and purchased low-cost medicines.

Breadth: Indian manufacturers can produce almost all essential medicines and, consequently, one manufacturer can supply the entire tender.

Quality credentials: Indian manufacturers have experience meeting stringent quality standards needed for exports to WHO and other stringent regulatory bodies, donor agreements, and the Pharmacy and Poisons Board (PPB).

History and Relationships: Indian generics played an important role in the roll-out of HIV treatment in Africa. Because of this, many African countries, including Kenya, have experienced trade and registration relationships with Indian companies.

Kenya was one of the first countries in sub-Saharan Africa to adopt the use of generic first-line HIV therapy in 2017 with funding from Unitaid.

The structure of the market strengthens the argument.

A 2017 export-promotion profile reported that Kenya’s pharmaceutical market is valued at $610 million,[8] and that 64 per cent of it is held by generics.

Additionally, the profile noted that Kenya’s strengths include having no import tariffs on pharmaceuticals, which makes landed prices low.

Lastly, the profile noted that more sophisticated treatments are imported; thus, the pull to established suppliers is strong.

This is also strengthened by the API layer.

Kenyan companies that formulate pharmaceuticals still buy their API from elsewhere, and according to Business Daily, 80 per cent of essential medicines that are not manufactured in Kenya are made in India and China, and are subject to price volatility.

Even Kenya’s pharmaceutical production is also reliant on the Indian supplier base.

Source of Kenya’s medicine importsIndicative shareNote
India~37–45% (2026 reporting);~53% (2016)Largest single source; broad generics across the essential list
Switzerland~7.7% (2016)Higher-value and originator products
Belgium~7.5% (2016)Higher-value and originator products
United Kingdom~6.5% (2016)Specialised and originator products
China~6.0% (2016)Generics and a major source of APIs
South Africa~3.2% (2016)Regional supply
Locally produced~20–30% of national demandKenyan manufacturers, reliant on imported APIs

The Fragility and the Tensions in the Dependence

Concentration is a vulnerability

the fragility and the tensions in the dependence

More than 70 per cent of Kenya’s essential medicines are imported from India, China and some European countries.

As a result, Kenya is susceptible to supply chain disruptions and drastic changes in medicine prices and costs.

Shortages of essential medicines have been attributed to disruptions in the global supply chain during the COVID-19 pandemic.

The suspension of donor-funded programs by the US poses a similar risk.

the fragility and the tensions in the dependence infographic

In January 2025, when foreign-assistance funding was frozen, the Sh 43 billion[9] PEPFAR (US President’s Emergency Plan for AIDS Relief) budget for the financial year October 2024 to September 2025 became uncertain.

The Ministry of Health said it was reaching out to other funders to bridge the financial gap.

The US embassy had reported in 2023 that in Kenya, PEPFAR supported the treatment of ARV medicine for 1.3 million people.[10]

In Kenyan media, it was reported that every single day of an interruption in PEPFAR services meant 17,000 HIV positive[11] Kenyans went without treatment.

A tightening quality bar read the 2025 directive correctly

In January 2025, the PPB sounded an alert against an influx of unregistered products referencing the Indian Pharmacopoeia.

The alert stated the Indian Pharmacopoeia has no regulatory authority in Kenya and that products referencing it are non-compliant.

Though headlines called it a ban, the notice does not prohibit Indian made medicines and instead targets unregistered products.

The overall direction is toward more stringent regulation, not to be more lax. Kenya is working to move from WHO Maturity Level 2 to Maturity Level 3 by December 2026, and industry players will be required to adopt GS1 standards for serialization and traceability.

This gives a competitive advantage to suppliers of registered medicines of quality and pushes away suppliers of substandard medicines.

Domestic governance failures compound the risk

There are problems with the public supply chain, too.

The Global Fund audit reported problems with the procurement of Sh3.7 billion of mosquito nets through KEMSA, and these were disputed by KEMSA.

Procurement of the mosquito nets was moved to the Global Fund’s wambo.org platform.

More recently, the Auditor General reported that KEMSA fulfilled only 41% of orders in 2024/25, against a target of 90%, and fill rates of 54, 50, 51 and 52%, in the previous years.

Donor-funded programs for HIV, TB and malaria and family planning reached only 79% of the targeted beneficiaries.

How Kenya Regulates and Procures Imported Medicine

Registration: the Pharmacy and Poisons Board

Foreign manufacturers submit product dossiers with the Pharmacy and Poisons Board (PPB) in the format known as CTD (Common Technical Document) in Modules 1 and 2, and a free-sale certificate or a WHO-PPC (Certificate of Pharmaceutical Product) from the country of origin.

Also provided are three samples of the smallest commercial pack from one batch, with batch certificates of analysis.

These samples are tested against the claimed in-house or pharmacopoeia specifications.

GMP (Good Manufacturing Practices) are points of interest.

The PPB does not register any product from any plant that does not comply with current GMP.

The PPB can verify compliance by doing an inspection of the site and requires a site master file where the plant has not been inspected.

This is why a pharmacopoeia with no standing in Kenya cannot be accepted as a substitute for registration.

Each foreign manufacturer requires a local agent, who is a registered wholesaler and has a power of attorney.

When creating a timeline for a plan, deadlines matter.

Complete new applications are processed within a year, with a 90-working-day fast track for locally manufactured and priority medicines.

Registrations are valid for five years. The process itself has deadlines and costs.

The profile gives $1,000 as the application fee and $6,000 for a GMP inspection of foreign facilities that have not been inspected.

If an applicant does not respond to a PPB query in six months, the application is treated as withdrawn. A rejected applicant can appeal within two months.

Renewal applications must be submitted at least three months before the expiry of the registration.

The profile is from 2018; therefore, confirm the fees and the processes with the PPB before filing.

Procurement: KEMSA, private wholesalers and donor channels

ChannelHow it worksWhat a supplier needs
KEMSA (public sector)State supplier; buys throughopen international tender and serves over 4,000 public facilitiesPPB registration, a competitive tender bid, reliable quality-assured supply
Donor-funded (Global Fund, PEPFAR)Finances HIV, TB and malaria commodities, with some procurement nowmoved to wambo.orgWHO prequalification or equivalent quality-assured status
Private sector (wholesalers, chains, MEDS)Commercial import and retail; themission-based MEDS also supplies facilitiesPPB registration and a licensed local distributor

Registration is the entry point to every procurement process.

The rules and the tenders change after registration, and those are the requirements against which the buyers assess the evidence.

In the same way, suppliers must also include payment and delivery risk.

There are reports that say 27 counties were cut off by KEMSA over an outstanding debt of Sh2.88 billion, and a Sh 499.7 million warehouse system to connect KEMSA stores in real time is still under construction.

A tender win does not remove commercial risk; it starts an Accounts Receivable and Logistics conversation.

What Kenya Actually Imports from India

We see a correlation between demand and disease burden.

A limited number of therapeutic areas dominate the volume, and India fulfils demand in all of these areas.

Therapeutic areaDemand driver in KenyaExample molecules from India
Anti-infectives / antibioticsBroad infectious-disease caseloadAmoxicillin, ceftriaxone, azithromycin
HIV / antiretrovirals~1.4 million people living with HIVTenofovir, lamivudine, dolutegravir (TLD)
Antimalarials3.5 million clinical cases a yearArtemether–lumefantrine, artesunate
Cardiovascular and anti-diabeticNCDs causing 39% of deathsAtorvastatin, metformin, gliclazide, amlodipine
TuberculosisTB listed among Kenya’s leading disease categoriesFirst- and second-line anti-TB agents
Maternal and reproductive healthMaternal-health and family-planning programmesOxytocin, iron–folic acid, contraceptives

The trend in the table continues. Most of India’s exports are finished products, especially drugs and pharmaceuticals.

In 2017-18, India’s exports to Kenya of drug formulations and biologicals were worth about US $200 million as compared to about US $33 million for bulk drugs and intermediates.

However, this analysis cautions that a significant part of India’s formulation imports is for further distribution in other countries in the region.

The donor channel is active in three of the six markets. KEMSA and its partners implement the programs for HIV, TB, malaria, and Family planning.

The Global Fund provides financing for HIV, TB and Malaria.

Therefore, WHO-prequalified and quality-assured supplies command a premium in these markets.

Indian vaccines were a smaller line, at about US$ 15 million in 2017-18.

Spending is moving. Kenya spent Sh62.1 billion on medicinal and pharmaceutical imports from January to September 2025, down from Sh79.6 billion in the same period in 2024, as buyers opted for cheaper alternatives.

Lower visibility in import statistics is due to demand for TB and maternal health products, which, however, follow the same pattern of buying cheaper alternatives.

These are, however, bought via public health programs.

HIV demonstrates the rapid evolution in product mix.

The rollout of the first generics of dolutegravir in Kenya in 2017 to treat HIV began with 20,000 patients.

Rollout to other countries like Nigeria and Uganda followed, and today the same is manufactured locally in Kenya.

Increasingly available generics of dolutegravir are also fast changing the product mix to include coverage for cardiovascular diseases, which include high blood pressure (hypertension) and diabetes.

Coverage for these conditions is bolstered by the National Hospital Insurance Fund (NHIF), which in 2016 introduced packages to cover diabetes, hypertension and cancer.

Where the Dependence Is Heading

There is substance to Kenya’s local manufacturing drive.

In October 2023, the President set a goal to locally manufacture at least 50% of the medicines on the Kenya Essential Medicines List by 2026 to cut the import bill by Sh76 billion.

Currently, PPB Guidance offers a 90-working-day fast track to locally manufactured products.

where the dependence is heading

In addition, Kenya-based Universal Corporation, in 2023, became the first African manufacturer to be WHO-prequalified to produce TLD, the Global Fund’s first line of defence against malaria, which the Global Fund is procuring for use in Mozambique.

A closer look at the situation is in order. The target for 2026 is moving, with local firms meeting between 20% and 30% of the demand and the import bill exceeding Sh100 billion.

Local producers still import APIs, and the increase in Kenyan manufacturers producing finished products increases the demand for APIs and finished products.

The future will probably not mean full self-reliance by replacing imports, but rather higher value add; more local finishing; greater demand for APIs and more complex formulations; and continued need for reliable and assured quality supply from outside the country.

Policymakers see this as well. The principal secretary of Kenya’s Industrialization Ministry asked why Indian pharma companies could not set up plants in Kenya to access the over 1.4 billion people market of the African Continental Free Trade Area.

WHO has a more cautious outlook on the milestone.

where the dependence is heading infographic

It says production alone will not achieve universal health coverage, and further advanced market commitments and fairer and more transparent procurement practices will be needed.

WHO also suggests that there will need to be continued technical assistance and support to the industry to sustainably manufacture medicines.

Kenyan industry has floated a proposal asking for 30 percent of government medicine procurement to be local.

This will change the dynamics of government tenders if adopted.

On regulation, PPB aims for maturity level 3 by the end of 2026 and mandates GS1 traceability.

This further leans towards assured quality and away from the lowest price in the market.

What This Means for a Quality-Assured Supplier

Large, import-reliant Kenya wants partners to raise its quality bar.

The partner it wants is a WHO-GMP manufacturer of finished formulations, one that properly registers each product to BP/USP and supplies quality-assured finished formulations to KEMSA and other private channels.

A partner like this, together with the partner Kenya is clearing out (i.e. shortcut operators), can help to meet Kenya’s growing demand for pharmaceuticals.

Actiza can be seen as the kind of partner that Kenya wants, i.e., one that can help Kenya move into local production as well as provide quality products for import.

Actiza manufactures APIs and Pharma Finished Products, which support local formulators and serve the public and private channel needs, respectively, and has various pharmaceutical certifications and quality assurances needed for PPB registration.  

Other potential partners can take advantage of Actiza’s supply and sourcing solutions in the East African region’s pharma sector.

They can discuss registration and other aspects of a potential business cooperation.

Frequently Asked Questions

Q1. What share of Kenya’s medicines come from India?

An exact figure does not exist. In 2026, it was estimated that India represented between 37% and 45% of Kenya’s pharmaceutical imports by value. An older trade database put it at 53% in 2016.

Since approximately 70% of Kenya’s medicines are imported, India undoubtedly has a significant role, but this share fluctuates by source, year, and method.

Q2. Did Kenya ban Indian medicines in 2025?

There was no nationwide ban on Indian manufactured drugs in 2025. In January, the PPB, in a public notice, cautioned the general public against using unregistered medicines that referenced the Indian Pharmacopoeia and said that the Indian Pharmacopoeia Commission does not enjoy any valid regulatory authority in Kenya.

Q3. How are medicines regulated and procured in Kenya?

There are plans in Kenya to outsource the regulation of some medicines. The procurement of medicines is through both the public and private sectors.

Kenya has been trying to lower its reliance on outsourcing by improving the capacity of its local pharmaceutical industry.

Products are registered with the PPB by means of a dossier, samples, certificates of analysis, and GMP compliance, and new applications are processed within 12 months.

Public sector procurement is predominantly through KEMSA’s public international tenders, with the remainder being donor procurement and private sector wholesalers.

Q4. Why does Kenya rely on India rather than manufacturing locally?

Local plants can only meet 20 to 30 per cent of local demand, and run at under 50 per cent of installed capacity. Imported APIs are required for finished products. India offers a better option from a cost and affordability perspective.

Q5. Is Kenya building its own pharmaceutical industry?

Yes, gradually. The target of local production of essential medicines at 50 per cent by 2026 is in place, and Universal Corporation has WHO prequalification for TLD. Expect this target to be extended, thus continuing dependence on imports.

Conclusion

It’s not just a ‘trade quirk’ that Kenya uses Indian generics.

It’s an example of a large, import-dependent health system meeting demand it cannot yet supply itself, at an affordable price from a reliable source, that makes almost everything on Kenya’s Essential Medicines List (EML).

This reliance also applies to Kenya’s pharmaceutical factories, which also rely on imported materials.

There’s also change. Kenya has raised the bar for pharmaceutical quality, removed sub-standard manufacturers, and developed the means to manufacture more medicines at home, but self-reliance isn’t the goal.

The long-term goal is a reliable, ‘quality’ supplier of finished medicines and Active Pharmaceutical Ingredients (APIs) for Kenya’s pharmaceutical industry.

Actiza team is able to discuss your upcoming registration, tenders, and Active Pharmaceutical Ingredients partnerships in Kenya and East Africa.

Arrange a meeting to discuss the East Africa and Kenya markets.

  1. https://www.capitalfm.co.ke/news/2023/12/kenya-says-1-4-million-living-with-hiv-majority-on-life-saving-drugs/
  2. https://www.standardmedia.co.ke/health/health-science/article/2001472749/kemsa-defends-sh37-billion-mosquito-nets-deal-amid-irregularities-claim
  3. https://www.standardmedia.co.ke/health/health-science/article/2001530001/who-warns-progress-slowing-on-non-communicable-diseases
  4. https://voanews.com/amp/kenya-makes-strides-toward-goal-of-eradicating-hiv-aids/7380196.html
  5. https://www.businessdailyafrica.com/bd/economy/value-of-pharma-imports-down-22pc-on-shift-to-cheap-products-5326982
  6. https://www.businessdailyafrica.com/bd/corporate/health/kenya-s-2026-local-medicine-target-slips-away-5507736
  7. https://www.standardmedia.co.ke/business/health-science/article/2001544437/kenya-pushes-to-cut-medicine-imports-as-east-africa-backs-local-production-drive
  8. https://pharmexcil.com/uploads/countryreports/Kenya_Regulatory_Market_Profile.pdf
  9. https://citizen.digital/article/kenya-faces-crisis-as-trumps-executive-order-to-cut-supply-of-hiv-malaria-drugs-n356674
  10. https://www.standardmedia.co.ke/amp/national/article/2001512000/kenyas-hiv-patients-victims-of-us-aid-freeze
  11. https://www.standardmedia.co.ke/health/amp/health-science/article/2001517650/uncertainty-as-kenya-struggles-to-fill-gaps-left-by-us-aid-freeze

About the Author

Nilesh Mendpara MD of ACTIZA PHARMA Profile Image
Nilesh Mendpara

Nilesh Mendpara is the Managing Director of Actiza Pharmaceutical PVT. LTD., based in Surat, Gujarat, India. With over 10 years of experience in the pharmaceutical industry, Nilesh is passionate about spreading pharmaceutical knowledge and staying ahead of industry trends. He holds a Master of Pharmacy (Distinction) and a Bachelor's in Pharmacy from Rajiv Gandhi University of Health Sciences. Under his leadership, Actiza Pharmaceutical aims to be the most trusted partner for pharmaceutical exports worldwide, ensuring the highest standards of quality and safety. Connect with Nilesh to explore opportunities in advancing global healthcare.

[Read more]
Request A Call Back

We are a 100% export-oriented company and do not engage in domestic sales within India.